Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1 CNS 1

Conditions

Melanoma 25 Neoplasms 8 Neoplasm Metastasis 8 Colorectal Neoplasms 5 Lymphoma, Non-Hodgkin 4 Leukemia, Hairy Cell 4 Multiple Myeloma 3 Carcinoma, Non-Small-Cell Lung 3 Wilms Tumor 2 Thyroid Neoplasms 2 Thyroid Cancer, Papillary 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Glioma 2 Ependymoma 2 Central Nervous System Neoplasms 2 Xanthogranuloma, Juvenile 1 Urinary Bladder Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Skin Neoplasms 1 Sarcoma, Clear Cell 1 Relapsed Pediatric Solid Tumor 1 Rare Tumour 1

Interventions

Temozolomide 73 Bevacizumab 58 Radiotherapy 40 Radiosurgery 28 Carboplatin 23 Nivolumab 17 Etoposide 17 Cisplatin 17 pembrolizumab 16 Irinotecan 16 Ipilimumab 15 Magnetic Resonance Spectroscopy 14 Erlotinib Hydrochloride 14 Cyclophosphamide 14 Carmustine 14 Pemetrexed 13 Topotecan 10 Surgical Procedures, Operative 10 Capecitabine 10 Lapatinib 9 Filgrastim 9 Trastuzumab 8 Thalidomide 8 Sunitinib 8 Paclitaxel 8 Lomustine 8 Aminolevulinic Acid 8 encorafenib 7 binimetinib 7 Vincristine 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Brain Neoplasms × Vemurafenib × Clear all

NCT03430947 2023-09-14

RadioCoBRIM

Technische Universität Dresden

Phase 2 Terminated

CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡